Archive

This in vitro study exposed DU-145 prostate cancer cells to extremely low-frequency pulsed electromagnetic fields (ELF P-EMF) at different intensities and times. The authors report increased cell mortality and apoptosis with higher intensity (22.6–35 mT) and longer exposure. They also report gene-expression changes…

This study reports that glioblastoma-specific amplitude-modulated 27.12 MHz RF electromagnetic fields (delivered intrabuccally) inhibited proliferation in several glioblastoma cell lines exposed 3 hours/day at patient-matched levels. The authors propose a mechanism involving CACNA1H and modulation of the “Mitotic…

This engineering study describes and simulates a helmet radio-frequency phased array applicator for Thermal Magnetic Resonance (ThermalMR), which combines MRI with targeted RF heating. Using EMF and temperature simulations in a phantom and human head model (including a modeled glioblastoma tumor volume), the authors…

This in vitro study exposed three ccRCC cell lines and a healthy kidney cell line (HEK293) to 50 Hz ELF-EMF at 4.5 mT for 30 minutes daily over 5 days. The authors report exposure-associated changes in expression of several genes (names not fully visible in the abstract), with differences between primary…

This in vitro study tested whether a 50 Hz, 20 mT extremely low-frequency electromagnetic field (ELF-EMF) enhances the cytotoxic effects of doxorubicin (DOX) in the MCF-7 breast cancer cell line. The authors report that combining ELF-EMF with low-dose DOX reduced cell viability at lower DOX concentrations than DOX…

This engineering/simulation study evaluates RF applicator array designs for Thermal Magnetic Resonance (ThermalMR), which combines MRI with RF hyperthermia for brain tumor theranostics. Using EMF and temperature simulations at 7.0 T, 9.4 T, and 10.5 T, hybrid loop+SGBT dipole arrays are reported to provide superior…

This single-site feasibility trial evaluated repeated 90-minute amplitude-modulated EMF exposure (AutEMdev) in 66 patients with advanced hepatocellular carcinoma. The primary focus was safety and hemodynamic variability during exposure, with exploratory outcomes including quality of life, survival, and tumor…

This review discusses low-energy amplitude-modulated RF EMF (27.12 MHz carrier with low Hz–kHz envelope modulation) delivered systemically via intrabuccal antenna devices as a potential treatment for advanced hepatocellular carcinoma. It reports preclinical inhibition of cancer growth in vitro and in mouse xenograft…

This study reports a noninvasive pulsed-burst electromagnetic field (PEMF) approach intended to protect against radiotherapy-induced bone loss. A 15 Hz, 2 mT PEMF waveform is described as producing distinctive calcium oscillations in osteoblasts and inhibiting radiation-related bone loss while not affecting other…

This study examined whether 900 MHz RF-EMF exposure modifies biological pathways associated with electrochemotherapy (ECT) in 4T1 cells and in mice bearing 4T1 tumors. At the highest reported power density (349 µW/cm), RF exposure was reported to increase ECT-induced tumor hypoxia and increase IFN-γ compared with ECT…

This animal study compared 50 Hz extremely low-frequency EMF exposure with doxorubicin (and their combination) in Walker-256 carcinosarcoma-bearing rats, assessing tumor growth and liver redox-related outcomes. DOX and DOX+EMF were reported to inhibit tumor growth more than EMF alone, though EMF alone also showed an…

This animal and in vitro study examined ELF magnetic field exposure in a mouse breast tumor model and a breast cancer cell line. The authors report tumor growth suppression and reduced expression of Ki-67, CD31, VEGFR2, and MMP-9 after exposure. They also report increased IFN-γ and TNF-α and increased…